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Volume 6Available online xxxBackground: Treatment with anti-PD-(L)1 antibodies, approved for several oncology indications, can lead to immune-
related adverse events (irAEs). We aimed to investigate risk factors associated with an increased reporting of irAEs in
patients treated with PD-(L)1 inhibitors approved for solid tumor indications.
Patients and methods: A retrospective review was performed of individual data from patients in phase II/III
registrational studies for PD-(L)1 inhibitors in solid tumors. Data on baseline characteristics and adverse events were
extracted. Univariate and multivariable logistic regression models were used to identify risk factors.
Results: In total, 5123 patients were included from 15 studies reporting on the use of four PD-(L)1 inhibitors for five
solid tumor indications. Univariate analysis suggested that type of study drug (P < 0.001), indication (P ¼ 0.003), body
mass index (BMI) (P ¼ 0.001), and baseline autoimmune disease (P < 0.001) were associated with an increased
occurrence of any irAE. Using logistic regression analyses, three factors were identified as increasing the risk of irAE:
BMI  30 kg/m2 [odds ratio (OR) 1.5, 95% confidence interval (CI) 1.2-1.8] in comparison to normal BMI, having an
autoimmune disease at baseline (OR 1.8, 95% CI 1.1-2.7), and use of a PD-L1 inhibitor (OR 1.6, 95% CI 1.2-2.0). The
latter finding is probably biased due to the selection of the studies in the dataset with complete information on
baseline characteristics.
Conclusion: This study was conducted using a large dataset of individual patient data from clinical trials comprising
multiple solid tumor indications. We demonstrated that patients with obesity and concurrent autoimmune disease
were at increased risk of developing irAEs.
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Treatment with anti PD-(L)1 antibodies blocks the ligande
receptor interaction in the tumor environment and
thereby facilitates enhanced antitumor immunity by
diminishing T-cell inhibitory activity.1-4 Immune checkpoint
inhibitors (ICIs) are a major development in anticancer
therapy and PD-(L)1 antibodies have shown anticancer
effects in a wide range of cancers and are approved by the
European Medicines Agency (EMA) and the Food and Drug
Administration (FDA) for various oncology indications.ondence to: Dr M.N. Hew, College ter beoordeling van Gen-
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- Issue 3 - 2021ICIs have a different toxicity profile than conventional
cytotoxic chemotherapy, with adverse events (AEs) usually
being less severe than those associated with chemother-
apies. These AEs in response to immunotherapy and asso-
ciated with an increased reactivity of the immune system
are defined as immune-related adverse events (irAEs). The
overall incidence rate of irAEs in patients treated with anti-
PD-(L)1 is ~26%, whereas the rate of severe-grade irAE in
these patients is 6%.5 It is important for clinicians to identify
the risk of irAEs early on, so that they may be treated when
needed or even be prevented.6-8 Therefore an overview of
risk factors that may increase or decrease the incidence and
severity of irAEs is helpful.
The aim of this study was to identify risk factors associ-
ated with the occurrence or severity of irAEs in patients
with solid tumors treated with anti-PD-(L)1 therapy. To our
knowledge this is the first study that uses a very large
dataset consisting of individual data including multiple PD-
(L)1 inhibitors, several indications, and a substantial numberhttps://doi.org/10.1016/j.esmoop.2021.100107 1
ESMO Open B. Gülave et al.of baseline characteristics, which enables a multifactorial
assessment of risk factors for the development of irAEs.
METHODS
Search strategy
All indications approved by the EMA for inhibitors of PD-1
and PD-L1 monotherapy for the treatment of solid tumors
were identified to be included in this study. For approval,
clinical study reports had to be submitted by the marketing
authorization holder (MAH) within the document manage-
ment system of the Medicines Evaluation Board (MEB).
Availability of individual study patient data of the submitted
phase II/III studies was assessed.Variables of interest
Baseline factors potentially associated with the risk of
experiencing an immune event were identified in the
available scientific literature.7,9-13 These included a history
of autoimmune disease, cardiovascular medication (antiar-
rhythmic and antihypertensive medication), antibiotics,
central nervous system (CNS)-related medication (anticon-
vulsants and antipsychotics), thyroid hormones, and body
mass index (BMI). The variables of interest were manually
extracted from individual data listings in the clinical study
report of the individual studies as presented by the MAH,
for example, treatment specifics (PD-1 or PD-L1 inhibitor,
indication, study identifier), patient characteristics (age
[years], gender, PD-L1 expression [%], smoking [yes/no],
weight, height, Eastern Cooperative Oncology Group
[ECOG] performance status), and data on irAEs (any irAE,
type and number of irAE(s), irAE grade 3).
For easy clinical reference, BMI, age, and comedication
were divided into categories; age was divided into cate-
gories 18-64, 65-74, and 75 years and BMI into under-
weight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2),
overweight (25.0-29.9 kg/m2), and obese (30 kg/m2).
Groups of comedication belonging to the same functional
class were grouped into antiarrhythmics, antihypertensives,
anticonvulsants, and antipsychotics (see Supplementary
Table S1, available at https://doi.org/10.1016/j.esmoop.
2021.100107).
With respect to PD-L1 expression, there is no uniform cut-
off used for PD-L1 positivity between the selected clinical
trials. To enable cross-study comparison, a consensus defi-
nition was laid upon the individual PD-L1 expression data.
The following consensus definition was used: no expression/
negative (<1%) or positive (1%) based on PD-L1 expression
on tumor cells as provided by the MAH.Collection of immune-related adverse events
IrAEs were collected according to the definitions given by the
MAHs. The criteria used for scoring of any irAE slightly
differed among MAHs. Overlapping in the definition was the
need for AEs (of special interest) to be categorized by the
MAH as ‘immune-related AEs’, when medical review was
considered consistent with an immune-mediated mechanism2 https://doi.org/10.1016/j.esmoop.2021.100107of action, when the use of systemic steroids or other
immunosuppressant or endocrine therapy was required, and
when there was no clear alternate etiology. Differences in the
definition of irAE between MAHs were related to time de-
pendency of the irAE, varying in that irAE should have started
after several days of treatment (thus excluding infusion re-
actions) or should occur within 30 or 100 days of treatment.
Most definitions required immunological, serological, and
histological evidence as support. A difference in grade de-
pendency was also observed between MAHs. For example,
some MAHs include a specific grade in the definition of irAE
or the need of dose modifications or use of systemic steroids,
whereas other MAHs did not include this specification. In all
dossiers only drug-related irAEs were collected. IrAEs were
divided into gastrointestinal (colitis, diarrhea), endocrine
(hypothyroidism, hyperthyroidism, adrenal insufficiency),
pulmonary (pneumonitis, interstitial lung disease), renal
(nephritis, increased blood creatinine), hepatic (alanine and
aminotransferase increase, autoimmune hepatitis), skin
(different types of rash), hypersensitivity (infusion related
reactions), others (any other organ that could be affected but
was uncommonly [2%] reported like neurological, ocular,
pancreatic, and cardiac), and irAE Common Terminology
Criteria for Adverse Events (CTCAE) grade 3 or higher.
Supplementary Table S4, available at https://doi.org/10.
1016/j.esmoop.2021.100107, provides an overview of which
irAEs belong to which system organ class.Statistical analysis
Statistical analyses were conducted using IBM SPSS statistical
software (version 20.0, Armonk, New York, USA) for Win-
dows. Descriptive characteristics were first explored using
frequencies and percentages. Next, potential risk factors for
any irAE were assessed by univariate analyses (histograms,
crosstabs, and chi-square test). The statistical significance
level of univariate analysis was determined by Pearson’s chi-
square test. A value of P < 0.05 was regarded as significant.
The selected variables with a significant difference in the
univariate analysis were included in the multivariable anal-
ysis. Multivariable analyses with logistic regression were
used to assess the association between multiple potential
risk factors and the occurrence of irAE. Model building was
performed in three steps. The first step was to build a ‘full’
model with irAE as dependent variable and all potential risk
factors as covariates. Risk factors with a P < 0.05 in the full
model were identified and a reduced model including only
these factors was compared with the full model. This testing
was performed by comparing the difference of 2 log like-
lihood of the full model and that of the reduced model.
Results are shown as odds ratio (OR) and 95% confidence
interval (CI) for the significant risk factors.RESULTS
Selection of clinical trials
Between 2015 and 2018, four PD-(L)1 inhibitors were
approved in the European Union as monotherapy for sevenVolume 6 - Issue 3 - 2021
PD-1 / PD-L1 study selection of 
oncology indications  (n=20)
18 studies selected as these
included populations with solid
tumors
2 studies excluded due to 
inclusion of non-solid tumors
15 studies* included over four 
different PD-1/PD-L1 inhibitors 





3 studies excluded due to 
missing data
 No demographics, 
comedication, AEs or irAE
listings of individual study 
subjects
Figure 1. Flowchart for the selection of clinical trials to identify risk factors
correlating with immune-related adverse events (irAEs) risk.
*Study name and clinical trial registry numbers (NCT) are available in
Supplementary Table S2, available at https://doi.org/10.1016/j.esmoop.2021.100107.
Table 1. Baseline characteristics of total study population (N [ 5123)




















Non-small-cell lung carcinoma 2204 (43.0)
Melanoma 1038 (20.3)
Urothelial cell carcinoma 988 (19.3)
Head and neck squamous cell carcinoma 483 (9.4)













Medication overview (N [ 5123)
B. Gülave et al. ESMO Openoncology indications. The dossiers underlying these mar-
keting approvals were based on 20 phase II and phase III
studies. In total, five studies were excluded due to the
following reasons: indication in non-solid tumors (Hodgkin’s
lymphoma; n ¼ 2), limited data (n ¼1), or missing key in-
dividual demographic data (n ¼ 2; Figure 1 and
Supplementary Table S2, available at https://doi.org/10.
1016/j.esmoop.2021.100107).Usage
Medication Yes, n (%) No, n (%) Missing, n (%)
Cardiovascularc 1988 (38.8) 2535 (49.5) 600 (11.7)
Antibiotics 479 (9.3) 4044 (78.9) 600 (11.7)
Central nervous systemd 988 (19.3) 3535 (69.0) 600 (11.7)
Steroids 639 (12.5) 3884 (75.8) 600 (11.7)
Allopurinol 145 (2.8) 4378 (85.5) 600 (11.7)
Salicylates 626 (12.2) 3897 (76.1) 600 (11.7)
Thyroid hormones 513 (10.0) 4010 (78.3) 600 (11.7)
Metformin 333 (6.5) 4190 (81.8) 600 (11.7)
a Missing due to empty fields in database and no submitted data.
b Missing, no data submitted in one study in patients with non-small-cell lung
carcinoma.
c Includes antiarrhythmic and antihypertensive medications; complete data missing
due to incomplete records of one study.
d Includes antipsychotics and anticonvulsants; complete data missing due to
incomplete records of one study.Characteristics of trials and study patients
In total, 15 clinical phase II/III monotherapy studies with
5123 study patients (defined as the total study population)
across five histologies were included. Four PD-(L)1 anti-
bodies, namely, nivolumab, pembrolizumab, durvalumab,
and atezolizumab, were evaluated (Supplementary Table S2,
available at https://doi.org/10.1016/j.esmoop.2021.100107).
Of the included study patients, 2204 (43.0%) were treated
for non-small-cell lung carcinoma (NSCLC), 1038 (20.3%) for
melanoma, 988 (19.3%) for urothelial carcinoma, 483 (9.4%)
for head and neck squamous cell carcinoma, and 410 (8.0%)
for renal cell carcinoma (Table 1). Several clinical trials were
performed per PD-(L)1 antibody with variable median
treatment duration. The nivolumab studies were performed
at a dosage of 3 mg/kg every 2 weeks, with the median
treatment duration ranging from 2.6 (CHECKMATE 057) to
6.5 months (CHECKMATE 066). The pembrolizumab studies
were performed at a dosage of 2 or 10 mg/kg every 2 or 3
weeks or at a fixed dose of 200 mg every 3 weeks, with
the median treatment duration ranging between 85
(KEYNOTE-040) and 183 days (KEYNOTE-006). Both atezoli-
zumab (1200 mg every 3 weeks) and durvalumab (10 mg/kg
every 2 weeks) had one single study entry (SupplementaryVolume 6 - Issue 3 - 2021Table S2, available at https://doi.org/10.1016/j.esmoop.
2021.100107).
As shown in Table 1, more men (67.6%) than women
(32.4%) had participated in the clinical trials. In the study
population, 2757 (53.8%) were between 18 and 64 years,
1657 (32.3%) between 65 and 74 years, and 709 (13.8%)
75 years. Moreover, 1865 (36.4%) patients had a normal
weight (BMI 18.5-24.9 kg/m2), 1416 (27.6%) were over-
weight (BMI 25.0-29.9 kg/m2), 787 (15.4%) were obesehttps://doi.org/10.1016/j.esmoop.2021.100107 3



















Non-small-cell lung carcinoma 1441 (33.8)
Melanoma 1003 (23.5)
Urothelial cell carcinoma 964 (22.6)
Head and neck squamous cell carcinoma 467 (10.9)




a Underweight, normal weight, overweight, and obese are defined as body mass
index <18.5 kg/m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2, and 30 kg/m2, respectively.
ESMO Open B. Gülave et al.(BMI 30 kg/m2), and 197 (3.8%) were underweight (BMI
<18.5 kg/m2). In this pooled analysis the main come-
dication used in the clinical trials was cardiovascular
medication, such as antihypertensive and antiarrhythmic
drugs (38.8%). Unfortunately the data records were not
complete for all study patients, as listings of medication use
at baseline and whether a patient had an autoimmune
disease were not available for 11.7% of the cases and BMI
was not available for 16.7% of the study population. A small
group of patients [112 (2.2%)] had an autoimmune disease
at baseline (Supplementary Table S3, available at https://
doi.org/10.1016/j.esmoop.2021.100107). Cases with missing
demographic data were used for the univariate analysis but
excluded for the multivariable analysis that used complete
cases. Table 2 shows the baseline characteristics of the
complete cases set.
PD-L1 expression was available in 2667 patients; 879
(17.2%) patients were scored as having negative expression
(<1%) and 1788 (34.9%) as having positive expression
(1%). In 2456 patients (47.9%) data on PD-L1 expression
was missing (Table 1). Because of a large amount of missing
data, the PD-L1 expression is not included in further
analyses.Immune-related adverse events
Overall, 19.2% (n ¼ 983) of the study population experi-
enced one or more irAE(s) (any grade), of whom 25% (n ¼
246) experienced a grade 3 irAE (Figure 2A; see
Supplementary Table S4, available at https://doi.org/10.
1016/j.esmoop.2021.100107, for an overview of scored
irAEs). irAEs were endocrine related (48%, n ¼ 471),
4 https://doi.org/10.1016/j.esmoop.2021.100107pulmonary related (21%, n ¼ 209), skin related (17%,
n ¼ 164), gastrointestinal related (10%, n ¼ 102), hepatic
related (5%, n ¼ 45), hypersensitivity related (5%, n ¼ 54),
renal related (2%, n ¼ 24), and other (n ¼ 38).
To assess which baseline patient-specific risk factors are
associated with an increased reporting of irAE during PD-1/
PD-L1 therapy, chi-square analyses were performed. Factors
significantly associated with developing an irAE (any grade)
were BMI (P ¼ 0.001), autoimmune disease (P < 0.001),
targeted indication (P ¼ 0.003), and specific study drug (P <
0.001; Figure 2B). For all the other factors no association
with irAEs could be determined. Risk factors for the
development of a grade 3 or higher irAE were autoimmune
disease (P < 0.001), cardiovascular medication (P ¼ 0.004),
salicylates (P ¼ 0.006), and thyroid hormones (P ¼ 0.010;
Supplementary Figure S1, available at https://doi.org/10.
1016/j.esmoop.2021.100107). For all the other factors
(e.g. gender, PD-L1 expression, smoking, ECOG) no associ-
ation with grade 3 irAE was shown.
To further assess the possible association of multiple
baseline risk factors and whether there is an increased risk
for the development of an irAE, multivariable logistic
regression was performed. The multivariable logistic regres-
sion was performed in the complete case set that included
only study patients for whom all variables of interest were
present and thus the dataset was complete. It comprised
83.3% (n ¼ 4265) of the total study population (see also
Table 2). As a post-hoc sensitivity analysis, univariate ana-
lyses were repeated using the complete cases set, which
confirmed the statistically significant associations of an irAE
with BMI, autoimmune disease, targeted indication, and
specific study drug. Within the complete case set, three
factors were identified for which the odds of experiencing
any grade irAE was significantly increased: patients with BMI
30 kg/m2 (obese) at baseline (OR 1.5, 95% CI 1.2-1.8)
compared with normal BMI (18.5-24.9 kg/m2), use of a PD-
L1 inhibitor (OR 1.6, 95% CI 1.2-2.0), and study patients lis-
ted as having an autoimmune disease at baseline (OR 1.8,
95% CI 1.2-2.7; Table 3). Patients with an autoimmune dis-
ease at baseline (OR 2.9, 95% CI 1.6-5.2) or patients using
salicylates at study entry (OR 1.6, 95% CI 1.1-2.3) were more
at risk of experiencing a grade 3 irAEs (Table 4).
As an exploratory analysis, we investigated whether there
was an association between certain risk factors and the
occurrence of irAEs within a specific organ system. Univar-
iate associations (P < 0.05) are not shown. For outcomes of
multivariable regression analyses per organ system, refer to
Table 4.DISCUSSION
In this retrospective study, we used a large dataset of
pooled individual patient data from clinical trials of anti
PD-(L)1-treated patients to identify risk factors associated
with irAE occurrence during treatment. To the best of our
knowledge, this is the first study with a very large study
population that includes multiple drugs, indications, and
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Figure 2. Occurrence of immune-related adverse events (IrAEs) and factors associated with developing any grade irAE in the total study population.
(A) Immune-related adverse events (irAEs) in the total study population. Percentages of subcategories are shown for the population that experienced at least one irAE,
which is 19% of the total study population. Others correspond to neurological, ocular, musculoskeletal, and pancreatic categories. Note: One patient could have multiple
irAEs in multiple categories, and therefore the sum of the experienced irAEs over the subcategories is not 100%. Refer to Supplementary Table S4, available at https://
doi.org/10.1016/j.esmoop.2021.100107, for the total number of patients per subcategory. (B) Factors significantly associated with developing any grade irAE in the total
study population based on chi-square analyses. HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung carcinoma; RCC, renal cell carcinoma; UCC,
urothelial carcinoma.
B. Gülave et al. ESMO Openpatient data from a prospective database systematically
documented during the treatment period.
In the study population of 5123 patients, 19% experi-
enced at least one irAE; among these patients, 25% expe-
rienced at least one severe irAE (grade 3). Our findings are
in line with the general incidence rate, which is reported to
be ~26%, with 23% being grade 3.14 Based on the final
prediction model in the complete case set for risk factors
associated with the occurrence of irAEs, three baseline risk
factors were identified to be associated with increased odds
of experiencing an irAE: being obese, the use of a PD-L1
inhibitor (compared with PD-1 inhibitor), and having an
autoimmune disease at baseline. Additional analysisVolume 6 - Issue 3 - 2021identified that autoimmune disease and salicylate use were
associated with greater odds of developing a grade 3 irAE.
Higher BMI has previously been reported to be associ-
ated with an increased risk of irAEs for patients treated with
PD-1/PD-L1 inhibitors.15-18 The mechanism behind this as-
sociation is not entirely clear. Cortellini et al.16,17 reported
an association between high BMI and increased irAEs and
additionally reported that responses and survival outcomes
were significantly better for overweight/obese patients
compared with normal weight patients. The association
between BMI and survival has indeed been previously
described19-21 in both patients treated with ICIs and other
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Table 3. Multivariable logistic regression of baseline factors associated
with increased risk for development of any grade irAE
Baseline characteristic
95% CI
OR Lower Upper P valueb
BMIa reference (normal weight) 0.001
BMI underweight 0.92 0.62 1.36 0.667
BMI overweight 1.17 0.98 1.39 0.083
BMI obese 1.49 1.22 1.82 <0.001
PD-1 versus PD-L1 1.59 1.24 2.04 <0.001
Autoimmune disease no versus yes 1.75 1.15 2.67 0.009
Hosmer and Lemeshow results showed chi-square ¼ 0.131; df ¼ 3; P ¼ 0.988. Test
population is 83.3% (n ¼ 4265) of the total study population; some data missing due
to empty records and non-submitted data. List of scored autoimmune diseases are
presented in Supplementary Table S3, available at https://doi.org/10.1016/j.
esmoop.2021.100107.
BMI, body mass index; CI, confidence interval; OR, odds ratio; PD-1, anti PD-1
treatment; PD-L1, anti-PD-L1 treatment.
a Underweight, normal weight, overweight, and obese are defined as BMI <18.5 kg/
m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2, and 30 kg/m2, respectively.
b Statistically significant when P < 0.05.





Autoimmune disease 2.9 1.6 5.2 0.001
Usage of salicylates 1.6 1.1 2.3 0.012
Endocrine
BMIa category 0.053
Underweight 1.1 0.7 1.8 0.779
Overweight 1.3 1.0 1.6 0.026
Obese 1.4 1.1 1.8 0.017
Study drug category 0.006
Gender male 0.8 0.7 1.0 0.047
Thyroid hormone usage 0.5 0.3 0.7 0.001
CNS medication usage 0.7 0.6 1.0 0.025
Constant 0.1 <0.001
Pulmonary
Study drug category <0.001




Underweight 0.3 0.0 2.1 0.214
Overweight 1.0 0.6 1.6 0.936
Obese 1.7 1.0 2.8 0.440
Study drug category 0.001
Autoimmune disease 2.9 1.2 6.8 0.016
Constant <0.001
Skin
Study drug category <0.001
Indication category 0.009
Melanoma 1.7 1.0 2.8 0.041
Urothelial 0.9 0.5 1.5 0.585
HNSCC 0.8 0.4 1.5 0.446
Renal cell carcinoma 0.2 0.4 1.6 0.547
Constant 0.1 <0.001
The complete case set is 83.3% (n ¼ 4265) of the total study population due to
missing data. This set included 199 patients with grade 3 irAEs, 439 patients with
endocrine irAEs, 161 patients with pulmonary irAEs, 91 patients with gastrointestinal
irAE, and 137 with skin irAEs. List of scored autoimmune diseases are presented in
Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2021.100107.
BMI, body mass index; CI, confidence interval; CNS, central nervous system; HNSCC,
head and neck squamous cell carcinoma; irAE, immune-related adverse event; OR,
odds ratio; PD-1, anti PD-1 treatment; PD-L1, anti-PD-L1 treatment.
a Underweight, normal weight, overweight, and obese are defined as BMI <18.5 kg/
m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2, and 30 kg/m2, respectively.
b Statistically significant when P < 0.05.
B. Gülave et al. ESMO Openand irAEs is an effect of increased survival or exposure to
PD-(L)1 inhibitors (e.g. by longer time on treatment or
increased exposure due to weight-based dosing) of patients
with high BMI remains unknown. Alternatively, because a
high BMI leads to a chronic, low-grade obesity-associated
inflammation, it could be hypothesized that this may
exacerbate immune-related toxicity. Besides, hypotheses
regarding obesity-associated increased expression of PD-1/
PD-L1 on immune cells, which facilitates targeting by anti-
PD-1/PD-(L)1, have been postulated.9,21,22 Further pro-
spective research on this subject is thus required.
In addition, having an autoimmune disease was associ-
ated with an increased risk of developing any grade and
severe irAE in patients using a ICI. While the clinical studies
used in our analysis had as exclusion criterion ‘active
autoimmune disease or which requires usage of systemic
steroids/immunosuppressants’, still 2.2% of the total study
population reported having at least one type of autoim-
mune disease, such as psoriasis or diabetes mellitus type 1.
In this group, 33% of the patients experienced any type of
irAE and had an increased risk of developing severe irAEs.
Other studies also reported an increased risk of developing
irAEs in patients with pre-existing autoimmune disease who
were treated with ICIs.,23e26 A retrospective study by Kehl
and colleagues27 showed that hospitalization due to irAE
was associated with pre-existing autoimmune disease. Two
other studies showed that nonactive/preexisting autoim-
mune disease did not increase irAE occurrence, but could
exacerbate previous autoimmune disease.28,29 Although it
cannot be excluded that in our study exacerbation of an
autoimmune disease may have played a role, it should be
noted that the aforesaid studies included a different patient
population. The previously published studies assessed a
smaller population (N < 125) and appeared to focus more
on patients with autoimmune disease, whereas our study
included a more general population of patients undergoing
PD-L1/PD-1 therapy, thus enabling a more solid comparison
between those with and without pre-existing autoimmune
disease and possibly explaining the found differences.Volume 6 - Issue 3 - 2021Furthermore, for severe irAEs, no studies have been
published describing the association of irAE development
with multiple risk factors. Evaluating risk factors that are
associated with more severe irAEs could be of importance
for clinical practice as increased monitoring or precautions
could be investigated to mitigate these risks. There was only
one small study that investigated factors associated with
severe irAEs in patients with NSCLC using univariate ana-
lyses, and it concluded that high tumor burden could in-
crease the risk of irAE.30 Therefore, the results presented
here could serve as a good starting point for further in-
depth research of the identified combinations of risk
factors.
With respect to the finding that study patients being
treated with a PD-L1 inhibitor have an increased risk of any
irAE occurrence compared with those treated with a PD-1
inhibitor, it should be noted that this finding might be
biased due to the selection of studies in the complete caseshttps://doi.org/10.1016/j.esmoop.2021.100107 7
ESMO Open B. Gülave et al.set and that the different studies used slightly different
criteria to score irAEs. The increased risk of irAEs with the
use of a PD-L1 inhibitor was concluded based on multi-
variable logistic regression performed using the complete
cases set. Compared with the total population, mainly pa-
tients using a PD-L1 inhibitor were excluded in the complete
cases set (see also Table 1) and no association was observed
in the total study population. In addition, conflicting find-
ings are reported in the literature. One systematic literature
analysis of patients with NSCLC showed that the toxicity
profile of PD-1 and PD-L1 inhibitors were similar,31 whereas
another meta-analysis in different cancer types reported a
lower incidence of any grade irAE when using PD-L1
compared with PD-1 inhibitors.15,32,33 The association
found in the complete cases set between the use of a PD-L1
inhibitor and the occurrence of irAEs is therefore likely to be
biased and definitive conclusions cannot be drawn based on
the dataset used in this study.
Previous studies suggest comedication as a possible fac-
tor in the development of autoimmunity.7,11 In our study,
comedication was not associated with the development of
irAEs in general, although in the exploratory analyses for
some specific organ sites, there were medications associ-
ated with an increased risk of an irAE. For example, salicy-
late use was identified as a risk increasing factor for severe
irAEs. On the contrary, it is hypothesized that salicylate use
could confer a protecting role through immune-suppression
mechanisms; however, no clinical studies have yet
confirmed this role.7 A possible explanation could be that
salicylate use is confounded with cardiovascular disease or
comorbidities, which we could not incorporate into our
multivariable model. Furthermore, for endocrine-related
irAEs, two types of comedication use at baseline showed
a risk decreasing effect: thyroid hormones and CNS-related
medication. In the literature, CNS medication has been
suggested as a risk increasing factor for the development of
autoimmune events.7 Concerning the effect of thyroid
hormones, no studies have been published; however,
because a majority of endocrine AEs include hypothyroid-
ism, it can be imagined that the use of thyroid hormones is
associated with a decreased risk of these AEs. Of note, for
the analyses of comedication the complete case set was
used, and therefore may be subject to selection bias while
data on comedication use during treatment were not
available.
Although our study has the advantage of using a large
dataset across a number of different anti PD-(L)1 treatment
options, there are several limitations. First, the dataset was
generated using available data from clinical studies that
were submitted as part of the marketing application dos-
siers. Even though the database was extensive, not all of the
data collected as part of the clinical trials were submitted
and the data records were not complete for all study pa-
tients. As there was no uniform data collection method
between studies, the inclusion of several factors into our
database was hindered, such as PD-L1 expression. Besides,8 https://doi.org/10.1016/j.esmoop.2021.100107there were small differences in irAE scoring definitions over
the studies as described in ‘Methods’ section. More spe-
cifically, some studies scored an irAE when it was above a
specific grade or when corticosteroids were needed, while
others scored every grade of the same type of irAE. Un-
fortunately this study did not include an assessment of
treatment outcomes such as overall survival and
progression-free survival due to incomplete data on an in-
dividual level. Finally, since we focused on the outcome of
an irAE, it should be recognized that the ability to observe
an irAE is dependent on a patient being able to survive long
enough to experience an irAE without experiencing another
event that led to treatment discontinuation. Unfortunately
we were not able to take such competing risks into account
in our analysis. While this may have an impact on the un-
derstanding of the exact causal relation between the risk
factor and irAEs, for clinical practice and management, the
interest is focused on the identification of potential risk
factors associated with experiencing an irAE. In the example
of BMI, if patients with a lower BMI are more at risk of
dying earlier, then they are also at lower risk of experiencing
an irAE. Thus, it is considered that the methods used to
identify risk factors in this study are valid for this research
question in the presence of competing risks.
Of note, there are also reports that time dependency of
toxicity did not influence survival in advanced melanoma
patients experiencing severe toxicity during checkpoint
blockade.17,34 Despite its limitations, the strength of the
study is the very large dataset which enabled us to identify
clinically relevant associations that may have otherwise
been hampered by a lack of power.
We believe that the addition of biological/histological
(PD-L1 expression, tumor burden) parameters or efficacy
(overall survival) and pharmacokinetic data (exposure)
could provide further insight into the development or irAEs.
The ultimate goal would be to use this on an individual
patient level and translate into the clinic, improving irAE
management and allowing to prevent and/or reduce irAE
occurrence in cancer patients treated with PD-(L)1
inhibitors.
In conclusion, in this study we showed that patients with
BMI 30 kg/m2 (obese) in comparison to patients with a
normal BMI and patients with an autoimmune disorder at
baseline are at an increased risk of developing an irAE
across cancer types and study drugs. For severe types of
irAEs, our model showed that having an autoimmune dis-
ease and salicylate use increase the risk of having an irAE.
Although our study indicates that several factors increase
the risks for development of irAEs, predicting which pa-
tients will or will not develop (severe) irAEs remains a
challenge as this is a multifactorial process. Nonetheless,
our results are considered relevant due to the large size of
the database, the use of studies which have systematically
and prospectively collected all AEs, and the assessment of
individual patient data taking into account multiple baseline
variables.Volume 6 - Issue 3 - 2021
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